Herman Waldmann

List of Publications by Year
in descending order

402 papers	36,526 citations	1994 101 h-index	3915 177 g-index
414 all docs	414 docs citations	414 times ranked	20457 citing authors

#	Article	IF	Citations
1	Reshaping human antibodies for therapy. Nature, 1988, 332, 323-327.	27.8	1,543
2	Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. New England Journal of Medicine, 2005, 352, 2598-2608.	27.0	1,028
3	Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature, 1984, 312, 548-551.	27.8	903
4	"Infectious" Transplantation Tolerance. Science, 1993, 259, 974-977.	12.6	830
5	CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.. Journal of Experimental Medicine, 1989, 170, 637-654.	8.5	618
6	Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.. Journal of Experimental Medicine, 1987, 166, 1351-1361.	8.5	604
7	Plasticity of Foxp3+ T Cells Reflects Promiscuous Foxp3 Expression in Conventional T Cells but Not Reprogramming of Regulatory T Cells. Immunity, 2012, 36, 262-275.	14.3	534
8	Identification of Regulatory T Cells in Tolerated Allografts. Journal of Experimental Medicine, 2002, 195, 1641-1646.	8.5	532
9	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 2000, 96, 2419-2425.	1.4	483
10	Heterogeneity of natural Foxp3 ⁺ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1903-1908.	7.1	481
11	Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2002, 100, 768-773.	1.4	472
12	The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 2006, 253, 98-108.	3.6	469
13	The plasticity and stability of regulatory T cells. Nature Reviews Immunology, 2013, 13, 461-467.	22.7	456
14	Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet, The, 1999, 354, 1691-1695.	13.7	447
15	Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet, The, 1998, 351, 1701-1702.	13.7	409
16	Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia. New England Journal of Medicine, 1986, 314, 202-207.	27.0	406
17	Induction of<i>foxP3</i>+ Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants. Journal of Immunology, 2004, 172, 6003-6010.	0.8	388
18	Both CD4+CD25+ and CD4+CD25â^’ Regulatory Cells Mediate Dominant Transplantation Tolerance. Journal of Immunology, 2002, 168, 5558-5565.	0.8	357

#	Article	IF	Citations
19	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 2002, 99, 4357-4363.	1.4	349
20	Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature, 1986, 323, 164-166.	27.8	337
21	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 2002, 99, 1071-1078.	1.4	333
22	The CAMPATHâ€1 antigen (CDw52). Tissue Antigens, 1990, 35, 118-127.	1.0	328
23	Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15059-15064.	7.1	328
24	Induction of classical transplantation tolerance in the adult.. Journal of Experimental Medicine, 1989, 169, 779-794.	8.5	311
25	Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet, The, 1992, 340, 748-752.	13.7	309
26	Induction of tolerance by monoclonal antibody therapy. Nature, 1986, 320, 449-451.	27.8	301
27	Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12055-12060.	7.1	293
28	Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia, 2010, 53, 614-623.	6.3	286
29	CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1999, 68, 1613-1616.	1.0	281
30	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology, 2005, 35, 3332-3342.	2.9	279
31	Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, The, 2005, 365, 1934-1941.	13.7	273
32	Induction of tolerance in peripheral T cells with monoclonal antibodies. European Journal of Immunology, 1990, 20, 2737-2745.	2.9	272
33	Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. International Immunology, 2004, 16, 1391-1401.	4.0	260
34	Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.. Journal of Experimental Medicine, 1988, 168, 127-142.	8.5	255
35	Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. Journal of Clinical Investigation, 2010, 120, 883-893.	8.2	253
36	In Vivo Transfer of GPI-Linked Complement Restriction Factors from Erythrocytes to the Endothelium. Science, 1995, 269, 89-92.	12.6	252

#	Article	IF	Citations
37	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain, 1996, 119, 225-237.	7.6	249
38	Monoclonal-Antibody Therapy in Systemic Vasculitis. New England Journal of Medicine, 1990, 323, 250-254.	27.0	246
39	IL-10 Gene Expression Is Controlled by the Transcription Factors Sp1 and Sp3. Journal of Immunology, 2000, 165, 286-291.	0.8	231
40	HOW DO MONOCLONAL ANTIBODIES INDUCE TOLERANCE? A Role for Infectious Tolerance?. Annual Review of Immunology, 1998, 16, 619-644.	21.8	227
41	Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.. Journal of Clinical Investigation, 1996, 98, 2819-2826.	8.2	227
42	Infectious tolerance. Current Opinion in Immunology, 1998, 10, 518-524.	5.5	225
43	Regulating the Immune Response to Transplants. Immunity, 2001, 14, 399-406.	14.3	222
44	The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. European Journal of Immunology, 1993, 23, 403-411.	2.9	213
45	Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation-Efficacy and Safety at Five Years. American Journal of Transplantation, 2005, 5, 1347-1353.	4.7	213
46	Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet, The, 1993, 341, 1620-1622.	13.7	204
47	Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response. Trends in Immunology, 1984, 5, 265-268.	7.5	200
48	Autoimmune Diabetes Onset Results From Qualitative Rather Than Quantitative Age-Dependent Changes in Pathogenic T-Cells. Diabetes, 2005, 54, 1415-1422.	0.6	197
49	Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis, 1984, 53, 265-271.	0.8	196
50	Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance. Journal of Immunology, 2000, 165, 4783-4786.	0.8	195
51	Mechanisms of Peripheral Tolerance and Suppression Induced by Monoclonal Antibodies to CD4 and CD8. Immunological Reviews, 1996, 149, 5-33.	6.0	191
52	Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. Journal of Experimental Medicine, 2011, 208, 2043-2053.	8.5	190
53	Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet, The, 1994, 344, 298-301.	13.7	189
54	Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection. Blood, 1998, 92, 4581-4590.	1.4	183

#	Article	IF	Citations
55	The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells. Nature Communications, 2011, 2, 269.	12.8	180
56	CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. European Journal of Immunology, 1987, 17, 1159-1165.	2.9	176
57	Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20920-20925.	7.1	176
58	Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood, 2004, 104, 948-955.	1.4	175
59	T CELL DEPLETION WITH CAMPATH-1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1988, 45, 753-758.	1.0	173
60	The immunogenicity of chimeric antibodies.. Journal of Experimental Medicine, 1989, 170, 2153-2157.	8.5	170
61	Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. European Journal of Immunology, 1991, 21, 1677-1684.	2.9	165
62	Regulatory T Cells Overexpress a Subset of Th2 Gene Transcripts. Journal of Immunology, 2002, 168, 1069-1079.	0.8	164
63	Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. European Journal of Immunology, 1994, 24, 2383-2392.	2.9	163
64	Tolerance to rat monoclonal antibodies. Implications for serotherapy.. Journal of Experimental Medicine, 1986, 163, 1539-1552.	8.5	161
65	Regulatory T cells and organ transplantation. Seminars in Immunology, 2004, 16, 119-126.	5.6	160
66	Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nature Immunology, 2002, 3, 1208-1213.	14.5	157
67	Risks of Developing Epstein-Barr Virusâ€“Related Lymphoproliferative Disorders After T-Cellâ€“Depleted Marrow Transplants. Blood, 1998, 91, 3079-3083.	1.4	153
68	T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. British Journal of Haematology, 1995, 89, 506-515.	2.5	152
69	Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. British Journal of Haematology, 1996, 94, 574-578.	2.5	152
70	The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. European Journal of Immunology, 1990, 20, 2747-2755.	2.9	151
71	The effect of treatment with Campath-1H in patients with autoimmune cytopenias. British Journal of Haematology, 2001, 114, 891-898.	2.5	151
72	Infectious tolerance and the long-term acceptance of transplanted tissue. Immunological Reviews, 2006, 212, 301-313.	6.0	151

#	Article	IF	Citations
73	Posttranscriptional Regulation of IL-10 Gene Expression Through Sequences in the 3â€²-Untranslated Region. Journal of Immunology, 2000, 165, 292-296.	0.8	150
74	Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight, 2017, 2, e89160.	5.0	150
75	CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplantation, 2000, 26, 69-76.	2.4	149
76	Generation of antiâ€inflammatory adenosine byleukocytes is regulated by TGFâ€Î². European Journal of Immunology, 2011, 41, 2955-2965.	2.9	148
77	AMPLIFICATION OF NATURAL REGULATORY IMMUNE MECHANISMS FOR TRANSPLANTATION TOLERANCE1. Transplantation, 1996, 62, 1200-1206.	1.0	145
78	IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT-MEDIATED LYSIS BY MONOCLONAL ANTIBODIES. European Journal of Immunology, 1988, 18, 1507-1514.	2.9	139
79	A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6709-6713.	7.1	139
80	Structural motifs involved in human IgG antibody effector functions. European Journal of Immunology, 1993, 23, 1098-1104.	2.9	139
81	Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It. Journal of Immunology, 2006, 176, 4632-4639.	0.8	139
82	Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Therapy, 1999, 6, 939-943.	4.5	137
83	CD73 and adenosine generation in the creation of regulatory microenvironments. Clinical and Experimental Immunology, 2012, 171, 1-7.	2.6	133
84	Regulation of CD40 function by its isoforms generated through alternative splicing. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1751-1756.	7.1	132
85	Directed differentiation of dendritic cells from mouse embryonic stem cells. Current Biology, 2000, 10, 1515-1518.	3.9	131
86	Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. European Journal of Immunology, 1992, 22, 805-810.	2.9	130
87	Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunological Reviews, 2003, 196, 109-124.	6.0	129
88	Immune privilege induced by regulatory T cells in transplantation tolerance. Immunological Reviews, 2006, 213, 239-255.	6.0	127
89	The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival. Frontiers in Immunology, 2017, 8, 1949.	4.8	127
90	PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1. Transplantation, 1999, 68, 1632-1637.	1.0	123

#	Article	IF	Citations
91	Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies. Immunological Reviews, 1992, 129, 165-201.	6.0	121
92	The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunological Reviews, 2001, 182, 164-179.	6.0	121
93	Mechanisms of monoclonal antibodyâ€facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFAâ€1) molecules in selfâ€nonâ€self discrimination. European Journal of Immunology, 1988, 18, 1079-1088.	2.9	120
94	SKIN ALLOGRAFT REJECTION BY L3/t4+ AND LYT-2+ T CELL SUBESTS. Transplantation, 1986, 41, 634-639.	1.0	117
95	Donor-specific transplantation tolerance: The paradoxical behavior of CD4+CD25+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10122-10126.	7.1	115
96	Self tolerance is Hâ€“2-restricted. Nature, 1984, 308, 738-741.	27.8	113
97	The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to Î² cells in NOD mice. European Journal of Immunology, 1992, 22, 1913-1918.	2.9	112
98	CAMPATH: from concept to clinic. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1707-1711.	4.0	110
99	Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Molecular Immunology, 1993, 30, 1089-1096.	2.2	108
100	Campath-1H therapy in refractory ocular inflammatory disease. British Journal of Ophthalmology, 2000, 84, 107-109.	3.9	105
101	Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis. Journal of Autoimmunity, 1998, 11, 255-264.	6.5	103
102	The Depletion of T Cell Subsets in Vitro and in Vivo. Transplantation, 1986, 42, 239-247.	1.0	100
103	Dendritic cells and prospects for transplantation tolerance. Current Opinion in Immunology, 2000, 12, 528-535.	5.5	94
104	The Human Interleukin 18 GeneIL18Maps to 11q22.2â€“q22.3, Closely Linked to the DRD2 Gene Locus and Distinct from Mapped IDDM Loci. Genomics, 1998, 51, 161-163.	2.9	93
105	Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood, 2001, 98, 467-474.	1.4	93
106	Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biology of Blood and Marrow Transplantation, 2004, 10, 186-194.	2.0	93
107	In vivo â€˜Purgingâ€™ of residual disease in CLL with Campathâ€1H. British Journal of Haematology, 1997, 97, 669-672.	2.5	92
108	A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clinical and Experimental Immunology, 1996, 106, 427-433.	2.6	89

#	Article	IF	Citations
109	Transplantation toleranceâ€”where do we stand?. Nature Medicine, 1999, 5, 1245-1248.	30.7	89
110	Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biology of Blood and Marrow Transplantation, 2003, 9, 257-265.	2.0	89
111	Reshaping a therapeutic CD4 antibody.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4181-4185.	7.1	88
112	A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. Journal of Immunological Methods, 1981, 44, 125-133.	1.4	86
113	Therapeutic potential of monovalent monoclonal antibodies. Nature, 1984, 308, 460-462.	27.8	86
114	Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation. Journal of Immunology, 2007, 179, 967-976.	0.8	86
115	Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmunity Reviews, 2016, 15, 726-735.	5.8	84
116	The use of monoclonal antibodies to achieve immunological tolerance. Trends in Immunology, 1993, 14, 247-251.	7.5	83
117	TGF-Î²â€“Mediated <i>Foxp3</i> Gene Expression Is Cooperatively Regulated by Stat5, Creb, and AP-1 through CNS2. Journal of Immunology, 2014, 192, 475-483.	0.8	83
118	Generation of Anergic and Regulatory T Cells following Prolonged Exposure to a Harmless Antigen. Journal of Immunology, 2004, 172, 5900-5907.	0.8	80
119	Exploiting Tolerance Processes in Transplantation. Science, 2004, 305, 209-212.	12.6	78
120	mTOR signalling and metabolic regulation of T cell differentiation. Current Opinion in Immunology, 2010, 22, 655-661.	5.5	78
121	Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. British Journal of Haematology, 1986, 64, 479-486.	2.5	77
122	TOLERANCE AND SUPPRESSION IN A PRIMED IMMUNE SYSTEM1. Transplantation, 1996, 62, 1614-1621.	1.0	77
123	Structure and chromosomal location of the mouse interleukin-12 p35 and p40 subunit genes. European Journal of Immunology, 1996, 26, 1222-1227.	2.9	76
124	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis and Rheumatism, 2001, 44, 1998-2008.	6.7	75
125	Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. British Journal of Haematology, 2002, 119, 1125-1132.	2.5	74
126	Immunoglobulin heavy chain locus of the rat: striking homology to mouse antibody genes.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6075-6079.	7.1	73

#	Article	IF	Citations
127	Embryonic stem cells and the challenge of transplantation tolerance. Trends in Immunology, 2004, 25, 465-470.	6.8	73
128	Critical Influence of Natural Regulatory CD25+ T Cells on the Fate of Allografts in the Absence of Immunosuppression. Transplantation, 2005, 79, 648-654.	1.0	72
129	Regulatory T cells in transplantation. Seminars in Immunology, 2006, 18, 111-119.	5.6	72
130	Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. British Journal of Haematology, 1985, 60, 41-48.	2.5	69
131	CAMPATH-1 Monoclonal Antibodies in Bone Marrow Transplantation. Stem Cells and Development, 1994, 3, 15-31.	1.0	69
132	Isolation of low-frequency class-switch variants from rat hybrid myelomÃ¡s. Journal of Immunological Methods, 1987, 103, 59-67.	1.4	68
133	Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood, 2010, 115, 1145-1155.	1.4	68
134	Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. Leukemia and Lymphoma, 1990, 2, 179-193.	1.3	67
135	Tmem176B and Tmem176A are associated with the immature state of dendritic cells. Journal of Leukocyte Biology, 2010, 88, 507-515.	3.3	67
136	The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. Journal of General Virology, 2002, 83, 2833-2844.	2.9	67
137	In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral Immunopathology. Journal of Virology, 2005, 79, 11935-11942.	3.4	66
138	Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. British Journal of Haematology, 2000, 108, 754-760.	2.5	65
139	The Role of Sp1 and NF-Î°B in Regulating CD40 Gene Expression. Journal of Biological Chemistry, 2002, 277, 8890-8897.	3.4	65
140	IL-10-Conditioned Dendritic Cells, Decommissioned for Recruitment of Adaptive Immunity, Elicit Innate Inflammatory Gene Products in Response to Danger Signals. Journal of Immunology, 2004, 172, 2201-2209.	0.8	65
141	A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. Journal of Immunology, 2010, 185, 763-768.	0.8	65
142	T Cell-dependent Mediator in the Immune Response. Nature, 1973, 243, 356-357.	27.8	64
143	Neutralizing Tumor Necrosis Factor Activity Leads to Remission in PatientsWith Refractory Noninfectious Posterior Uveitis. JAMA Ophthalmology, 2004, 122, 845.	2.4	64
144	Protection and privilege. Nature, 2006, 442, 987-988.	27.8	64

#	Article	IF	Citations
145	Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression. Clinical Immunology and Immunopathology, 1989, 51, 38-54.	2.0	63
146	Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends in Immunology, 2005, 26, 130-135.	6.8	63
147	Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment. Frontiers in Immunology, 2014, 5, 409.	4.8	63
148	Connecting the mechanisms of Tâ€cell regulation: dendritic cells as the missing link. Immunological Reviews, 2010, 236, 203-218.	6.0	62
149	IMMUNE RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS. Transplantation, 2000, 69, 1341-1347.	1.0	62
150	Reconstitution of the Epstein-Barr virusâ€“specific cytotoxic T-lymphocyte response following T-cellâ€“depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 839-842.	1.4	61
151	Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regenerative Medicine, 2009, 4, 513-526.	1.7	61
152	Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Therapy, 2012, 19, 78-85.	4.5	61
153	Conditions Determining the Generation and Expression of T Helper Cells. Immunological Reviews, 1977, 35, 121-145.	6.0	60
154	A Key Role for TGF-Î² Signaling to T Cells in the Long-Term Acceptance of Allografts. Journal of Immunology, 2007, 179, 3648-3654.	0.8	60
155	Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes. Cell Reports, 2018, 24, 1610-1626.	6.4	60
156	The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplantation, 2000, 25, 411-417.	2.4	59
157	Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up. Transplantation, 2009, 87, 1092-1095.	1.0	59
158	Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1989, 48, 428-429.	0.9	58
159	MS4A4B Is a GITR-Associated Membrane Adapter, Expressed by Regulatory T Cells, Which Modulates T Cell Activation. Journal of Immunology, 2009, 183, 4197-4204.	0.8	58
160	CAMPATH-1H in multiple sclerosis. Multiple Sclerosis Journal, 1996, 1, 357-365.	3.0	57
161	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 2007, 82, 93-105.	3.3	57
162	Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy. Current Stem Cell Research and Therapy, 2009, 4, 70-80.	1.3	57

#	Article	IF	Citations
163	TGF-Î² in transplantation tolerance. Current Opinion in Immunology, 2011, 23, 660-669.	5.5	57
164	Enhanced Production of IL-10 by Dendritic Cells Deficient in CIITA. Journal of Immunology, 2005, 174, 1222-1229.	0.8	56
165	Harnessing FOXP3+ regulatory T cells for transplantation tolerance. Journal of Clinical Investigation, 2014, 124, 1439-1445.	8.2	56
166	Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. Cellular Immunology, 1989, 122, 377-390.	3.0	55
167	Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. European Journal of Immunology, 1992, 22, 2825-2830.	2.9	55
168	Expansion of Foxp3⁺ Tâ€cell populations by <i>Candida albicans</i> enhances both Th17â€cell responses and fungal dissemination after intravenous challenge. European Journal of Immunology, 2014, 44, 1069-1083.	2.9	55
169	The Influence of the Major Histocompatibility Complex on the Function of T-Helper Cells in Antibody Formation. Immunological Reviews, 1978, 42, 202-223.	6.0	54
170	CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. British Journal of Haematology, 1993, 84, 542-544.	2.5	54
171	T-cell depletion with Campath-1H â€˜in the bagâ€™ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. British Journal of Haematology, 2003, 121, 109-118.	2.5	54
172	Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. Journal of Neuroimmunology, 1993, 45, 1-14.	2.3	52
173	Immune reconstitution at 6 months following t-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation, 2002, 74, 1551-1559.	1.0	52
174	ANTI-GLOBULIN RESPONSES TO RAT AND HUMANIZED CAMPATH-1 MONOCLONAL ANTIBODY USED TO TREAT TRANSPLANT REJECTION1. Transplantation, 1999, 68, 1417-1419.	1.0	52
175	Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. Journal of Molecular Biology, 1992, 227, 971-976.	4.2	51
176	Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye, 1995, 9, 564-569.	2.1	51
177	Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation. Nature, 1978, 274, 166-168.	27.8	50
178	COMPARISON OF CAMPATH-1 PLUS COMPLEMENT, ANTI-T CELL RICIN A CHAIN IMMUNOTOXIN, AND SOYBEAN AGGLUTININ ALONE OR IN COMBINATION WITH SHEEP ERYTHROCYTES OR IMMUNOMAGNETIC BEADS. Transplantation, 1989, 47, 984-988.	1.0	50
179	Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clinical and Experimental Immunology, 2007, 110, 158-166.	2.6	50
180	Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-Iâ€“driven CD8+ T cell response. Journal of Experimental Medicine, 2018, 215, 1987-1998.	8.5	50

#	Article	IF	Citations
181	Induction of Immunological Tolerance/Hyporesponsiveness in Baboons with a Nondepleting CD4 Antibody. Journal of Immunology, 2004, 173, 4715-4723.	0.8	49
182	A humanized monovalent CD3 antibody which can activate homologous complement. European Journal of Immunology, 1991, 21, 2717-2725.	2.9	48
183	Monoclonal antibodies as agents to reinducetolerance in autoimmunity. Journal of Autoimmunity, 1992, 5, 93-102.	6.5	48
184	Cooperation across the histocompatibility barrier. Nature, 1975, 258, 728-730.	27.8	47
185	In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy, 2001, 3, 197-201.	0.7	47
186	Dominant transplantation tolerance. Current Opinion in Immunology, 2003, 15, 499-506.	5.5	47
187	Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biology of Blood and Marrow Transplantation, 2004, 10, 867-876.	2.0	47
188	Complement activation by immunoglobulin does not depend solely on C1q binding. European Journal of Immunology, 1990, 20, 277-281.	2.9	46
189	The involvement of Ly 2+ T cells in beta cell destruction. Journal of Autoimmunity, 1990, 3, 101-109.	6.5	46
190	A Personal History of the CAMPATH-1H Antibody. Medical Oncology, 2002, 19, S03-S10.	2.5	46
191	Peripheral tolerance mechanisms prevent the development of autoreactive T cells in chimeras grafted with two minor incompatible thymuses. European Journal of Immunology, 1989, 19, 111-117.	2.9	45
192	Structural basis for ligand-mediated mouse GITR activation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 641-645.	7.1	45
193	Infectious tolerance: therapeutic potential. Current Opinion in Immunology, 2010, 22, 560-565.	5.5	45
194	Human Monoclonal Antibodies: The Benefits of Humanization. Methods in Molecular Biology, 2019, 1904, 1-10.	0.9	45
195	Advantages of rat monoclonal antibodies. Trends in Immunology, 1983, 4, 100-101.	7.5	44
196	T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly. British Journal of Haematology, 2003, 123, 309-322.	2.5	44
197	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapyâ€induced lymphopenia: Twelveâ€year outcomes. Arthritis and Rheumatism, 2008, 58, 370-375.	6.7	44
198	The failure to show a necessary role for C3 in thein vitro antibody response. European Journal of Immunology, 1975, 5, 185-193.	2.9	43

#	Article	IF	Citations
199	A Role for Regulatory T Cells in Acceptance of ESC-Derived Tissues Transplanted Across an Major Histocompatibility Complex Barrier Â. Stem Cells, 2010, 28, 1905-1914.	3.2	43
200	Foxp3 Expression Is Required for the Induction of Therapeutic Tissue Tolerance. Journal of Immunology, 2012, 189, 3947-3956.	0.8	43
201	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
202	THE MAJOR HISTOCOMPATIBILITY SYSTEM AND THE IMMUNE RESPONSE. British Medical Bulletin, 1978, 34, 253-258.	6.9	42
203	The improved lytic function andin vivo efficacy of monovalent monoclonal CD3 antibodies. European Journal of Immunology, 1989, 19, 381-388.	2.9	42
204	Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunology, Immunotherapy, 1990, 31, 236-242.	4.2	42
205	Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.. British Journal of Ophthalmology, 1995, 79, 1054-1055.	3.9	42
206	Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I Î±1 Domain. Blood, 1997, 90, 3629-3639.	1.4	42
207	EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIA. Transplantation, 1999, 67, 620-626.	1.0	42
208	The CD59 antigen â€•a multifunctional molecule. Tissue Antigens, 1992, 40, 213-220.	1.0	41
209	Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance. Science Translational Medicine, 2011, 3, 68ra10.	12.4	41
210	Cell-surface markers on haemopoietic precursors. Reagents for the isolation and analysis of progenitor cell subpopulations. Molecular and Cellular Probes, 1987, 1, 297-326.	2.1	40
211	Sustained remission of severe resistant autoimmune neutropenia with Campathâ€•1H. British Journal of Haematology, 1997, 97, 306-308.	2.5	40
212	Dickkopf-3, a Tissue-Derived Modulator of Local T-Cell Responses. Frontiers in Immunology, 2015, 6, 78.	4.8	40
213	THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE-COMMON ANTIGEN. Transplantation, 1985, 40, 538-544.	1.0	39
214	Active suppression induced by anti-CD4. European Journal of Immunology, 1993, 23, 965-968.	2.9	39
215	Partial and transient modulation of the CD3â€“Tâ€•cell receptor complex, elicited by lowâ€•dose regimens of monoclonal antiâ€•CD3, is sufficient to induce disease remission in nonâ€•obese diabetic mice. Immunology, 2010, 130, 103-113.	4.4	39
216	Limiting dilution analysis of cells of the immune system II: What can be learnt?. Trends in Immunology, 1984, 5, 295-298.	7.5	38

#	Article	IF	Citations
217	Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?. Bone Marrow Transplantation, 2002, 30, 797-804.	2.4	38
218	Tolerance: an overview and perspectives. Nature Reviews Nephrology, 2010, 6, 569-576.	9.6	38
219	The influence of thymus on the development of MHC restrictions exhibited by T-helper cells. Nature, 1979, 277, 137-138.	27.8	37
220	THE REPOPULATION CAPACITY OF BONE MARROW GRAFTS FOLLOWING PRETREATMENT WITH MONOCLONAL ANTIBODIES AGAINST T LYMPHOCYTES IN RHESUS MONKEYS. Transplantation, 1988, 45, 301-306.	1.0	37
221	The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4+ T cells. Frontiers in Immunology, 2017, 8, 218.	4.8	37
222	Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. Transplant International, 2003, 16, 66-75.	1.6	36
223	Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. Journal of Clinical Pharmacology, 2010, 50, 1238-1248.	2.0	36
224	Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. Journal of Clinical Investigation, 2004, 113, 1754-1762.	8.2	36
225	A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection. European Journal of Immunology, 1997, 27, 1663-1670.	2.9	35
226	Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 827-834.	2.4	35
227	Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target. PLoS ONE, 2009, 4, e7848.	2.5	35
228	Reprogramming the immune system: coâ€receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunological Reviews, 2008, 223, 361-370.	6.0	34
229	Loss of the TGFÎ²-Activating Integrin Î±vÎ²8 on Dendritic Cells Protects Mice from Chronic Intestinal Parasitic Infection via Control of Type 2 Immunity. PLoS Pathogens, 2013, 9, e1003675.	4.7	34
230	Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. European Journal of Immunology, 1991, 21, 847-850.	2.9	33
231	CD8 + Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus. Journal of Virology, 2005, 79, 12264-12272.	3.4	33
232	Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 7719-7723.	7.1	32
233	THE EFFECT OF AGLYCOSYLATION ON THE IMMUNOGENICITY OF A HUMANIZED THERAPEUTIC CD3 MONOCLONAL ANTIBODY. Transplantation, 1995, 60, 847-853.	1.0	32
234	Serial analysis of gene expression provides new insights into regulatory T cells. Seminars in Immunology, 2003, 15, 209-214.	5.6	32

#	Article	IF	Citations
235	A Novel Role for Triglyceride Metabolism in Foxp3 Expression. Frontiers in Immunology, 2019, 10, 1860.	4.8	32
236	Reprogramming the immune system. Immunological Reviews, 2002, 185, 227-235.	6.0	31
237	Embryonic stem cells: a novel source of dendritic cells for clinical applications. International Immunopharmacology, 2005, 5, 13-21.	3.8	31
238	Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins. Journal of Immunological Methods, 1984, 69, 207-214.	1.4	30
239	Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody fab fragment and its humanized counterpart 1 1Edited by I. A. Wilson. Journal of Molecular Biology, 1998, 284, 85-99.	4.2	30
240	Anti-adhesion Molecule Therapy as an Interventional Strategy. Clinical Immunology, 1999, 93, 93-106.	3.2	30
241	Therapeutic approaches for transplantation. Current Opinion in Immunology, 2001, 13, 606-610.	5.5	30
242	Regulatory Cells and Transplantation Tolerance. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015545-a015545.	6.2	30
243	Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Medicine, 2018, 10, 71.	8.2	30
244	Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Experimental Hematology, 1999, 27, 1210-1218.	0.4	29
245	Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Transplantation, 2001, 27, 1053-1058.	2.4	29
246	Resistance of regulatory T cells to glucocorticoid-viduced TNFR family-related protein (GITR) duringPlasmodium yoelii infection. European Journal of Immunology, 2005, 35, 3516-3524.	2.9	29
247	Regulation and Privilege in Transplantation Tolerance. Journal of Clinical Immunology, 2008, 28, 716-725.	3.8	29
248	Enhanced Efficacy from Gene Therapy in Pompe Disease Using Coreceptor Blockade. Human Gene Therapy, 2015, 26, 26-35.	2.7	29
249	Antiâ€‹<scp>CD</scp>3 treatment upâ€regulates programmed cell death proteinâ€1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology, 2017, 151, 248-260.	4.4	29
250	CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. European Journal of Immunology, 1999, 29, 156-167.	2.9	28
251	Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?. Transplantation Proceedings, 2004, 36, 1225-1227.	0.6	28
252	Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning. BMC Immunology, 2006, 7, 9.	2.2	28

#	Article	IF	Citations
253	Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. Immunology Letters, 2010, 128, 108-115.	2.5	28
254	Prevention of Diabetes but not Insulitis in NOD Mice Injected with Antibody to CD4. Journal of Autoimmunity, 1993, 6, 301-310.	6.5	27
255	Embryonic stem cells: protecting pluripotency from alloreactivity. Current Opinion in Immunology, 2007, 19, 596-602.	5.5	27
256	STRAIN VARIATION IN SUSCEPTIBILITY TO MONOCLONAL ANTIBODY-INDUCED TRANSPLANTATION TOLERANCE1. Transplantation, 1997, 63, 1570-1573.	1.0	27
257	Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. Journal of Nuclear Medicine, 2006, 47, 1335-41.	5.0	27
258	Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting. British Journal of Haematology, 1986, 62, 421-430.	2.5	26
259	Suppression in murine experimental autoimmune thyroiditis: In vivo inhibition of CD4+ T cell-mediated resistance by a nondepleting rat CD4 monoclonal antibody. Cellular Immunology, 1991, 138, 185-196.	3.0	26
260	Antibody-Induced Transplantation Tolerance: The Role of Dominant Regulation. Immunologic Research, 2003, 28, 181-192.	2.9	26
261	Fc-Disabled Anti-Mouse CD40L Antibodies Retain Efficacy in Promoting Transplantation Tolerance. American Journal of Transplantation, 2008, 8, 2265-2271.	4.7	26
262	Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase. Journal of Dermatological Science, 2011, 61, 144-147.	1.9	26
263	Tolerance induction to human stem cell transplants with extension to their differentiated progeny. Nature Communications, 2014, 5, 5629.	12.8	26
264	Apoptosis: potential for disease therapies. Trends in Immunology, 1998, 19, 291-293.	7.5	25
265	Isolation, molecular characterization, and tissue-specific expression of ECP-51 and ECP-54 (TIP49), two homologous, interacting erythroid cytosolic proteins. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1446, 365-370.	2.4	25
266	Tolerance can be infectious. Nature Immunology, 2008, 9, 1001-1003.	14.5	25
267	DOMINANT TOLERANCE AND LINKED SUPPRESSION INDUCED BY THERAPEUTIC ANTIBODIES DO NOT DEPEND ON FAS-FASL INTERACTIONS1. Transplantation, 2000, 69, 1683-1689.	1.0	25
268	Monogamous T helper cell. Nature, 1977, 268, 641-642.	27.8	24
269	CD8+ T-Cell Depletion and Rapamycin Synergize with Combined Coreceptor/Stimulation Blockade to Induce Robust Limb Allograft Tolerance in Mice. American Journal of Transplantation, 2008, 8, 2527-2536.	4.7	24
270	Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Transplant Immunology, 1995, 3, 305-312.	1.2	23

#	Article	IF	Citations
271	Optimism after much pessimism: what next?. Current Opinion in Immunology, 1999, 11, 589-591.	5.5	23
272	Enhancement of humoral and cellular immunity with an antiâ€glucocorticoidâ€induced tumour necrosis factor receptor monoclonal antibody. Immunology, 2010, 130, 231-242.	4.4	23
273	Regulatory T cells and transplantation tolerance. Immunotherapy, 2013, 5, 717-731.	2.0	23
274	Properties of educated T cells. The ability of educated T cells to facilitate the immune response to non-cross-reacting antigensin vitro. European Journal of Immunology, 1973, 3, 167-172.	2.9	22
275	Structure and chromosomal location of mouse and human CD52 genes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1446, 334-340.	2.4	22
276	From Laboratory to Clinic. Methods in Molecular Medicine, 2000, 40, 243-266.	0.8	22
277	Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. Transplant International, 2003, 16, 66-75.	1.6	22
278	Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. Cytotherapy, 2000, 2, 5-14.	0.7	21
279	Stable lines of genetically modified dendritic cells from mouse embryonic stem cells. Transplantation, 2003, 76, 606-608.	1.0	21
280	Secreted and Transmembrane 1A Is a Novel Co-Stimulatory Ligand. PLoS ONE, 2013, 8, e73610.	2.5	21
281	T cell dependence of B cell unresponsivenessin vitro. European Journal of Immunology, 1974, 4, 410-416.	2.9	20
282	BLOCKING OF CYTOTOXIC T CELL FUNCTION BY MONOCLONAL ANTIBODIES AGAINST THE CD45 ANTIGEN		

#	Article	IF	Citations
289	Monoclonal antibodies for the induction of transplantation tolerance. Current Opinion in Immunology, 1993, 5, 753-758.	5.5	19
290	Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up. Leukemia and Lymphoma, 1997, 25, 479-486.	1.3	19
291	T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4. European Journal of Immunology, 1997, 27, 495-499.	2.9	19
292	Mechanisms of immunological tolerance. Clinical Biochemistry, 2016, 49, 324-328.	1.9	19
293	Semi-Specific Immuno-Absorption and Monoclonal Antibody Therapy in ANCA Positive Vasculitis: Experience in Four Cases. Autoimmunity, 1998, 28, 163-171.	2.6	18
294	Probing Dendritic Cell Function by Guiding the Differentiation of Embryonic Stem Cells. Methods in Enzymology, 2003, 365, 169-186.	1.0	18
295	Biomarkers of Transplantation Tolerance: More Hopeful than Helpful?. Frontiers in Immunology, 2011, 2, 9.	4.8	18
296	Segregation of mouse hemopoietic progenitor cells using the monoclonal antibody, YBM/42. Journal of Cellular Physiology, 1983, 115, 37-45.	4.1	17
297	Depletion of CD4⁺and CD8⁺Cells Eliminates Immunologic Memory of Thyroiditogenicity in Murine Experimental Autoimmune Thyroiditis. Autoimmunity, 1994, 19, 161-168.	2.6	17
298	What can be done to prevent graft versus host disease?. Current Opinion in Immunology, 1994, 6, 777-783.	5.5	17
299	High Level Transcription of the Complement Regulatory Protein CD59 Requires an Enhancer Located in Intron 1. Journal of Biological Chemistry, 1999, 274, 710-716.	3.4	17
300	Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. Bone Marrow Transplantation, 2005, 36, 675-682.	2.4	17
301	Tolerogenicity is not an absolute property of a dendritic cell. European Journal of Immunology, 2010, 40, 1728-1737.	2.9	17
302	Th17 Cells Induce a Distinct Graft Rejection Response That Does Not Require IL-17A. American Journal of Transplantation, 2012, 12, 835-845.	4.7	17
303	The characterisation of monoclonal antibodies against haemopoietic cells: Comparison of an immunoperoxidase method with fluorescence activated cell sorting. Journal of Immunological Methods, 1983, 61, 171-182.	1.4	15
304	The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. International Journal of Cancer, 1988, 41, 15-17.	5.1	15
305	A Humanised Therapeutic CD4 mAb Inhibits TCR-Induced IL-2, IL-4, and IL-10 Secretion and Expression of CD25, CD40L, and CD69. Cellular Immunology, 1998, 185, 101-113.	3.0	15
306	Campath-1 Abs â€˜in the bagâ€™ for hematological malignancies: the Cape Town experience. Cytotherapy, 2004, 6, 172-181.	0.7	15

#	Article	IF	Citations
307	CD3 Monoclonal Antibodies: A First Step Towards Operational Immune Tolerance in the Clinic. Review of Diabetic Studies, 2012, 9, 372-381.	1.3	15
308	Low dose unresponsiveness with a thymus independent antigen. Nature, 1975, 258, 730-731.	27.8	14
309	The development of insulin-dependent diabetes mellitus in non-obese diabetic mice: the role of CD4+ and CD8+ T cells. Biochemical Society Transactions, 1991, 19, 187-191.	3.4	14
310	Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies. Tissue Antigens, 1994, 43, 155-162.	1.0	14
311	Therapeutic aspects of tolerance. Current Opinion in Pharmacology, 2001, 1, 392-397.	3.5	14
312	The new immunosuppression. Current Opinion in Chemical Biology, 2003, 7, 476-480.	6.1	14
313	Gene Expression in the <i>Gitr</i> Locus Is Regulated by NF-ÎºB and Foxp3 through an Enhancer. Journal of Immunology, 2014, 192, 3915-3924.	0.8	14
314	Cooperation across the histocompatibility barrier: H2d T cells primed to antigen in an H-2d environment can cooperate with H-2k B cells.. Journal of Experimental Medicine, 1976, 144, 1707-1711.	8.5	13
315	Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways. Molecular Immunology, 1987, 24, 587-594.	2.2	13
316	Sequence of a rat immunoglobulin y2c heavy chain constant region cDNA: extensive homology to mouse y3. European Journal of Immunology, 1988, 18, 317-319.	2.9	13
317	Cell Replacement Therapy and the Evasion of Destructive Immunity. Stem Cell Reviews and Reports, 2005, 1, 159-168.	5.6	13
318	Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Molecular Genetics and Metabolism Reports, 2014, 1, 446-450.	1.1	13
319	Induced Foxp3+ T Cells Colonizing Tolerated Allografts Exhibit the Hypomethylation Pattern Typical of Mature Regulatory T Cells. Frontiers in Immunology, 2016, 7, 124.	4.8	13
320	Detection of monoclonal antibodies against cell surface antigens: the use of antiglobulins coupled to red blood cells. Journal of Immunological Methods, 1984, 66, 81-87.	1.4	12
321	Isolation and expression of cDNA encoding the canine CD4 and CD8Î± antigens. Tissue Antigens, 1994, 43, 184-188.	1.0	12
322	The new immunosuppression: just kill the T cell. Nature Medicine, 2003, 9, 1259-1260.	30.7	12
323	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 299-306.	0.5	12
324	Regulatory T Cells: Context Matters. Immunity, 2009, 30, 613-615.	14.3	12

#	Article	IF	Citations
325	Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance. American Journal of Transplantation, 2014, 14, 1678-1689.	4.7	12
326	Dominant regulation. Immunologic Research, 1999, 20, 1-14.	2.9	11
327	Extrathymic signals regulate the onset of T cell repertoire selection. European Journal of Immunology, 2000, 30, 1948-1956.	2.9	10
328	CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development. Frontiers in Immunology, 2018, 9, 1381.	4.8	10
329	Coreceptor blockade targeting CD4 and CD8 allows acceptance of allogeneic human pluripotent stem cell grafts in humanized mice. Biomaterials, 2020, 248, 120013.	11.4	10
330	Monoclonal Antibodies for Organ Transplantation: Prospects for the Future. American Journal of Kidney Diseases, 1988, 11, 154-158.	1.9	9
331	Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries. Bone Marrow Transplantation, 1998, 22, 117-124.	2.4	9
332	A novel role for Glucocorticoid-Induced TNF Receptor Ligand (Gitrl) in early embryonic zebrafish development. International Journal of Developmental Biology, 2010, 54, 815-825.	0.6	9
333	Human Monoclonal Antibodies: The Residual Challenge of Antibody Immunogenicity. Methods in Molecular Biology, 2014, 1060, 1-8.	0.9	9
334	Evidence for the inactivation of precursor B cells in high dose unresponsiveness. Nature, 1976, 264, 780-782.	27.8	8
335	The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2005, 5, 397-411.	1.8	8
336	Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes. Frontiers in Immunology, 2018, 9, 1006.	4.8	8
337	Genetic Modification of Dendritic Cells Through the Directed Differentiation of Embryonic Stem Cells. Methods in Molecular Biology, 2007, 380, 59-72.	0.9	8
338	CD4 mAbs PREVENT PROGRESSION OF ALLOACTIVATED CD4+ T CELLS INTO THE S PHASE OF THE CELL CYCLE WITHOUT INTERFERING WITH EARLY ACTIVATION SIGNALS1. Transplantation, 1996, 62, 1136-1143.	1.0	8
339	EPSTEIN-BARR VIRUS (EBV) ASSOCIATED B-CELL LYMPHOPROLIFERATIVE DISEASE FOLLOWING HLA IDENTICAL SIBLING MARROW TRANSPLANTATION FOR APLASTIC ANAEMIA IN A PATIENT WITH AN EBV SERONEGATIVE DONOR. Transplantation, 1999, 67, 1373-1375.	1.0	8
340	The use of monoclonal antibodies to achieve immunological tolerance. Trends in Pharmacological Sciences, 1993, 14, 143-148.	8.7	7
341	Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy, 2004, 6, 450-456.	0.7	7
342	Regulatory T cells and transplantation tolerance: <i>Emerging from the darkness?</i>. European Journal of Immunology, 2021, 51, 1580-1591.	2.9	7

#	Article	IF	Citations
343	Approaching Tolerance in Transplantation. International Archives of Allergy and Immunology, 2001, 126, 11-22.	2.1	6
344	Reprogramming the Immune System Using Antibodies. , 2006, 333, 247-268.		6
345	Special regulatory T cell review: The suppression problem!. Immunology, 2008, 123, 11-12.	4.4	6
346	Preservation of recall immunity in antiâ€CD3â€treated recent onset type 1 diabetes patients. Diabetes/Metabolism Research and Reviews, 2011, 27, 925-927.	4.0	6
347	CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment. PLoS ONE, 2016, 11, e0161618.	2.5	6
348	HIGH DOSE BONE MARROW TRANSPLANTATION INDUCES DELETION OF ANTIGEN-SPECIFIC T CELLS IN A FAS-INDEPENDENT MANNER1. Transplantation, 2000, 69, 1676-1682.	1.0	6
349	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 2000, 96, 2419-2425.	1.4	6
350	B Cell Activation. Immunological Reviews, 1975, 23, 213-222.	6.0	5
351	Direct antibody rosette-forming reactions using monoclonal markers of lymphocyte subpopulations. Journal of Immunological Methods, 1986, 92, 241-249.	1.4	5
352	Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 659-663.	4.0	5
353	A Bacterial Artificial Chromosome Reporter System for Expression of the Human FOXP3 Gene in Mouse Regulatory T-Cells. Frontiers in Immunology, 2017, 8, 279.	4.8	5
354	Infectious tolerance. What are we missing?. Cellular Immunology, 2020, 354, 104152.	3.0	5
355	Monoclonals and marrow transplants. Nature, 1986, 323, 586-586.	27.8	4
356	Limiting Dilution Analysis. , 1998, , 1584-1586.		4
357	Immunological Tolerance. Frontiers in Immunology, 2010, 1, 102.	4.8	4
358	Interaction of Rat Monoclonal Antibodies with Human Killer Cells. , 1985, 186, 797-803.		4
359	Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. Bone Marrow Transplantation, 1997, 20, 709-710.	2.4	3
360	Development and clinical use of CAMPATHÂ® 1H. Transplantation Reviews, 2003, 17, S5-S7.	2.9	3

#	Article	IF	Citations
361	Transplantation tolerance: the big picture. Where do we stand, where should we go?. Clinical and Experimental Immunology, 2017, 189, 135-137.	2.6	3
362	Tolerance Induction in the Peripheral Immune System. , 1993, , 149-155.		3
363	Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection. Blood, 1998, 92, 4581-4590.	1.4	3
364	Therapeutic Potential of Monoclonal Antibodies to the Leucocyte Common Antigen. , 1985, 186, 805-812.		3
365	How many T cells help one B cell?. Seminars in Immunopathology, 1980, 3, 129-44.	4.0	2
366	Allosuppression: evidence for the involvement of both â€œnoncytotoxicâ€•and cytotoxic T cells. European Journal of Immunology, 1984, 14, 645-651.	2.9	2
367	Tolerance induction in the adult: â€˜dangerâ€™ at Le Bischenberg. Trends in Immunology, 1995, 16, 121-123.	7.5	2
368	Transplantationâ€”caught in the crossfire!. Nature Immunology, 2002, 3, 803-804.	14.5	2
369	Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 80-89.	0.9	2
370	Activation rather than <scp>F</scp>oxp3 expression determines that <scp>TGF</scp>â€Î²â€induced regulatory <scp>T</scp> cells outâ€compete naÃ¯ve <scp>T</scp> cells in dendritic cell clustering. European Journal of Immunology, 2012, 42, 1436-1448.	2.9	2
371	Drug minimization in transplantation. Current Opinion in Organ Transplantation, 2014, 19, 331-333.	1.6	2
372	Induction of Immunological Tolerance as a Therapeutic Procedure. Microbiology Spectrum, 2016, 4, .	3.0	2
373	The Monogamous T helper cell. , 1979, , 403-412.		2
374	Interaction of rat monoclonal antibodies with human killer cells (K cells). Biochemical Society Transactions, 1984, 12, 877-878.	3.4	1
375	Monoclonal Antibodies for Immunosuppression. Chemical Immunology and Allergy, 1988, 45, 16-30.	1.7	1
376	Therapeutic immunosuppression of T cells. Current Opinion in Biotechnology, 1992, 3, 668-674.	6.6	1
377	Prospects for the Application of Antibodies in Medicine. Methods in Molecular Medicine, 2000, 40, 63-72.	0.8	1
378	Regulation and privilege in transplantation. Current Opinion in Organ Transplantation, 2007, 12, 340-344.	1.6	1

#	Article	IF	Citations
379	Robert Royston Amos (Robin) Coombs. 9 January 1921 â€" 25 January 2006. Biographical Memoirs of Fellows of the Royal Society, 2009, 55, 45-58.	0.1	1
380	Immunohematopoietic stem cell transplantation in Cape Town. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 320-332.	0.9	1
381	A step closer to effective transplant tolerance?. Nature Medicine, 2012, 18, 664-665.	30.7	1
382	Antibody immunogenicity: does bioprocessing hold all the answers?. Pharmaceutical Bioprocessing, 2015, 3, 175-177.	0.8	1
383	Pharmacologically Modified Dendritic Cells: A Route to Tolerance-associated Genes. , 0, , 619-647.		1
384	SAGE Analysis of Cell Types Involved in Tolerance Induction. Methods in Molecular Biology, 2007, 380, 225-251.	0.9	1
385	Ectopic Transplantation of Tissues Under the Kidney Capsule. , 0, , 347-354.		1
386	Monoclonal Antibodies for the Depletion of Specific Subpopulations of Lymphocytes. Novartis Foundation Symposium, 1987, 129, 194-208.	1.1	1
387	Tolerance Induction with CD4 Monoclonal Antibodies. Novartis Foundation Symposium, 1998, 215, 146-158.	1.1	1
388	(5) Induction of remission in systemic vasculitis with monoclonal antibody Campath-1H. British Journal of Dermatology, 1989, 121, 72-75.	1.5	0
389	Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: Comment on the article by Isaacs et al. Arthritis and Rheumatism, 2002, 46, 1973-1974.	6.7	0
390	Contact Between Good Friends: What Limiting Dilution Analysis Taught Us. Scandinavian Journal of Immunology, 2005, 62, 30-32.	2.7	0
391	Immune Privilege and Tolerance â€" Therapeutic Antibody Approaches. , 0, , 350-370.		0
392	Regulation of the immune response. Current Opinion in Immunology, 2010, 22, 549-551.	5.5	0
393	THE ANTIBODY PROBLEM AND THE GENERATION OF MONOCLONAL ANTIBODIES. , 2011, , 197-215.		0
394	Regulatory T-cells in Therapeutic Transplantation Tolerance. , 2008, , 325-333.		0
395	Defining and Overcoming the Immunological Barriers to Stem Cell Therapies. , 2008, , 59-80.		0
396	A Theoretical Framework for Self-tolerance and its Relevance to Therapy of Autoimmune Disease. , 1989, , 127-133.		0

#	Article	IF	Citations
397	Induction of Immunological Tolerance as a Therapeutic Procedure. , 0, , 771-785.		0
398	The evolution of therapeutic antibodies. , 2020, , 296-298.		0
399	Targeting CD4 for the induction of dominant tolerance. , 2008, , 49-56.		0
400	Reprogramming the immune system. Clinical Transplants, 2008, , 351-62.	0.2	0
401	SAGE Analysis of Cell Types Involved in Tolerance Induction. , 0, , 225-252.		0
402	Genetic Modification of Dendritic Cells Through the Directed Differentiation of Embryonic Stem Cells. , 0, , 59-72.		0